Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

Phase 2 Unknown 20 enrolled Institute of Hematology & Blood Diseases Hospital, China

NaSingle-groupOpen-labelTreatment

Summary

Age is no longer a barrier to successful allogeneic hematopoietic cell transplantation. However, the incidence of aGVHD is still high among the elderly, especially for patients receiving HID-HSCT. We designed this clinical trial to use humanized CD25 antibody for aGVHD prophylaxis among in elderly patients aged 50 and older. The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.

Timeline

Start: 2023-07-07
Primary completion: 2024-05-07
Completion: 2024-05-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Humanized CD25 antibody	Unknown	1 mg/kg	Intravenous

Indications

No indication recorded.